Flubromazolam’s position in medical trials is restricted as a consequence of its classification to be a designer drug. Having said that, its outcomes are already reversed through the benzodiazepine antagonist flumazenil in pharmacokinetic studies, furnishing insights into its scientific implications and unexpected emergency management of overdos